CY1121921T1 - Φαρμακευτικα σκευασματα - Google Patents

Φαρμακευτικα σκευασματα

Info

Publication number
CY1121921T1
CY1121921T1 CY20191100471T CY191100471T CY1121921T1 CY 1121921 T1 CY1121921 T1 CY 1121921T1 CY 20191100471 T CY20191100471 T CY 20191100471T CY 191100471 T CY191100471 T CY 191100471T CY 1121921 T1 CY1121921 T1 CY 1121921T1
Authority
CY
Cyprus
Prior art keywords
hydrazinocarbonyl
thien
methanesulfonyl
pyridinium
crystals
Prior art date
Application number
CY20191100471T
Other languages
English (en)
Inventor
Chaitanya Dutt
Jaya Abraham
Vivek Mishra
Amit Kesarwani
Ramesh Chandra Gupta
Shailesh Deshpande
Shital Kumar ZAMBAD
Anoop Mathur
Jignesh Kotecha
Sachin Latad
Manish Patel
Anita Chaudhari
Original Assignee
Torrent Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Limited filed Critical Torrent Pharmaceuticals Limited
Publication of CY1121921T1 publication Critical patent/CY1121921T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε φαρμακευτικά σκευάσματα που περιλαμβάνουν 1-(2-θειεν-2'-υλ-2-οξοαιθυλ)-3-(μεθανοσουλφονυλ-υδραζινοκαρβονυλ)πυριδίνιο, τα φαρμακευτικώς αποδεκτά άλατα, συγκρυστάλλους-άλατα και συγκρυστάλλους αυτού, συγκεκριμένα χλωριούχο 1-(2-θειεν-2'-υλ-2-οξο-αιθυλ)-3-(μεθανοσουλφονυλ-υδραζινοκαρβονυλ) πυριδίνιο. Τα σκευάσματα είναι κατάλληλα για χορήγηση από του στόματος και επίσης περιλαμβάνουν ενισχυτή διαπερατότητας ή κατάλληλη βάση ή μείγμα αυτών. Τα σκευάσματα της παρούσας εφεύρεσης προορίζονται για τη θεραπεία ασθενειών που σχετίζονται με τελικά προϊόντα προχωρημένης γλυκοζυλίωσης.
CY20191100471T 2015-04-08 2019-05-03 Φαρμακευτικα σκευασματα CY1121921T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1475MU2015 2015-04-08
PCT/IB2016/051920 WO2016162787A1 (en) 2015-04-08 2016-04-05 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
CY1121921T1 true CY1121921T1 (el) 2020-10-14

Family

ID=55808800

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100471T CY1121921T1 (el) 2015-04-08 2019-05-03 Φαρμακευτικα σκευασματα

Country Status (30)

Country Link
US (1) US10772879B2 (el)
EP (1) EP3280447B1 (el)
JP (1) JP6736656B2 (el)
KR (1) KR20170134662A (el)
CN (1) CN107530287B (el)
AR (1) AR104185A1 (el)
AU (1) AU2016246124B2 (el)
BR (1) BR112017021669A2 (el)
CA (1) CA2997463A1 (el)
CY (1) CY1121921T1 (el)
DK (1) DK3280447T3 (el)
EA (1) EA037041B1 (el)
ES (1) ES2724629T3 (el)
HR (1) HRP20190783T1 (el)
HU (1) HUE044889T2 (el)
IL (1) IL254794B (el)
LT (1) LT3280447T (el)
MX (1) MX2017012942A (el)
MY (1) MY182008A (el)
PH (1) PH12017501829A1 (el)
PL (1) PL3280447T3 (el)
PT (1) PT3280447T (el)
RS (1) RS58708B1 (el)
SG (1) SG11201708142XA (el)
SI (1) SI3280447T1 (el)
TR (1) TR201906476T4 (el)
TW (1) TWI713512B (el)
UA (1) UA123051C2 (el)
WO (1) WO2016162787A1 (el)
ZA (1) ZA201707094B (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3169368A1 (en) 2012-06-15 2014-01-09 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
ES2882530T3 (es) 2013-03-22 2021-12-02 Univ Nova Southeastern Partículas finas de epinefrina y métodos para uso de las mismas para el tratamiento de condiciones que responden a la epinefrina
CA3116730A1 (en) * 2018-10-19 2020-04-23 Nova Southeastern University Sublingual epinephrine compositions including ph-modifying excipients and penetration enhancers and methods for use thereof
KR102330597B1 (ko) * 2020-04-17 2021-11-26 보령제약 주식회사 무정형의 엠파글리플로진을 포함하는 안정성이 향상된 신규 약제학적 제형

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE386508T1 (de) * 1999-02-22 2008-03-15 Merrion Res I Ltd Feste orale dosierungsform enthaltend einen resorptionsverstärker
HU227523B1 (en) * 1999-10-06 2011-07-28 Torrent Pharmaceuticals Ltd Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
ES2243389T3 (es) 2001-03-21 2005-12-01 Torrent Pharmaceuticals Ltd Compuestos de piridinio utiles para el tratamiento de enfermedades relacionadas con los age.
JP2009529005A (ja) 2006-03-03 2009-08-13 トレント・ファーマシューティカルズ・リミテッド アンジオテンシン１受容体（ａｔ１）とエンドセリンａ（ｅｔａ）受容体に対する新規な二重作用受容体拮抗薬（ｄａｒａ）
JP2009023932A (ja) * 2007-07-18 2009-02-05 Tama Tlo Kk Ｎ−メチルピリジニウム化合物を有効成分として含有する抗ウイルス剤、それを含有する、抗ウイルス組成物、食餌及び動物用飼料
JP2011510067A (ja) * 2008-01-25 2011-03-31 トレント・ファーマシューティカルズ・リミテッド 組合せ医薬品
CN101574343B (zh) * 2008-05-07 2011-06-01 吉林大学 一种治疗糖尿病的药物组合物
EP2427432A2 (en) * 2009-05-07 2012-03-14 Torrent Pharmaceuticals Limited Novel heterocyclic compounds
JP2013514976A (ja) * 2009-12-16 2013-05-02 ノッド ファーマシューティカルズ， インコーポレイテッド 経口薬物送達のための組成物および方法
CN104069066B (zh) * 2013-03-25 2017-04-19 吉林大学 黄癸固体分散体及其在治疗糖尿病及并发症中的应用

Also Published As

Publication number Publication date
TR201906476T4 (tr) 2019-05-21
EA037041B1 (ru) 2021-01-29
ZA201707094B (en) 2021-04-28
AU2016246124A1 (en) 2017-11-02
AU2016246124B2 (en) 2019-11-14
AR104185A1 (es) 2017-07-05
EP3280447B1 (en) 2019-02-27
SI3280447T1 (sl) 2019-06-28
JP2018510916A (ja) 2018-04-19
US20180110763A1 (en) 2018-04-26
BR112017021669A2 (pt) 2018-07-10
JP6736656B2 (ja) 2020-08-05
RS58708B1 (sr) 2019-06-28
DK3280447T3 (da) 2019-05-13
EA201792237A1 (ru) 2018-02-28
LT3280447T (lt) 2019-05-27
ES2724629T3 (es) 2019-09-12
MY182008A (en) 2021-01-18
IL254794A0 (en) 2017-12-31
PH12017501829A1 (en) 2018-04-23
MX2017012942A (es) 2018-01-30
TW201642858A (zh) 2016-12-16
HUE044889T2 (hu) 2019-11-28
PT3280447T (pt) 2019-05-14
PL3280447T3 (pl) 2019-07-31
UA123051C2 (uk) 2021-02-10
CN107530287B (zh) 2020-11-10
HRP20190783T1 (hr) 2019-06-28
WO2016162787A1 (en) 2016-10-13
IL254794B (en) 2021-05-31
KR20170134662A (ko) 2017-12-06
CN107530287A (zh) 2018-01-02
CA2997463A1 (en) 2016-10-13
SG11201708142XA (en) 2017-11-29
TWI713512B (zh) 2020-12-21
EP3280447A1 (en) 2018-02-14
US10772879B2 (en) 2020-09-15

Similar Documents

Publication Publication Date Title
CY1124432T1 (el) Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη
CY1121921T1 (el) Φαρμακευτικα σκευασματα
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
CY1124484T1 (el) 2-ετεροαρυλο-3-οξο-2,3-διυδροπυριδαζινο-4-καρβοξαμιδια για τη θεραπευτικη αντιμετωπιση του καρκινου
CY1125292T1 (el) Παραγωγα 6,7,8,9-tetpaϋδpo-3h-πypazoλo[4,3-f iσοκινολινης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
CY1122792T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου
CY1124548T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
CY1121698T1 (el) Υγρο σκευασμα για εισπνοη που περιεχει rpl554
CY1117584T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1
CY1124970T1 (el) Παραγωγα συγχωνευμενων δακτυλιων πυραζολιου και μεθοδος παρασκευης αυτων και εφαρμογη αυτων σε αντιμετωπιση καρκινων, φλεγμονης και νοσων του ανοσοποιητικου
CY1126109T1 (el) Αναστολεις toy trpc6
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
EA201890654A1 (ru) Терапевтические композиции для лечения вируса иммунодефицита человека
CY1121326T1 (el) Υποκατεστημενη 2,4 διαμινο-κινολινη ως νεοι αντικαρκινικοι παραγοντες
CY1123494T1 (el) Enωσeiς etepoapyλo-kapboξamiδioy ως anaσtoλeiς thς ripk2
CY1117504T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, και cx3cr1
EA201792591A1 (ru) Фармацевтические препараты
CY1124907T1 (el) Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
CY1122892T1 (el) Παραγωγα 3-(καρβοξυμεθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου